Regeneneron报告说,2025年Q4收入的EPS和固定收入较低,宣布新的合作,并支付红利。 Regeneron reports Q4 2025 earnings with lower EPS and flat revenue, announces new collaboration, and pays dividend.

Regenenron制药公司定于2026年1月30日报告2025年的Q4收入情况,分析家预测EPS为10.74美元,比一年前的12.07美元有所下降,收入为37.9亿美元,与上一年同期持平。 Regeneron Pharmaceuticals is set to report Q4 2025 earnings on January 30, 2026, with analysts projecting $10.74 EPS, down from $12.07 a year ago, and revenue of $3.79 billion, flat year-over-year. 该公司于12月1日宣布与Tessera治疗公司开展全球合作,开发TSRA-196。 The company announced a global collaboration with Tessera Therapeutics on December 1 to develop TSRA-196. 分析师已提高价格目标，Evercore ISI以875美元领先。 Analysts have raised price targets, with Evercore ISI leading at $875. Regeneron的股票以749.44美元关闭,下降了0.2%,该公司计划在当天支付0.09美元的股息。 Regeneron’s stock closed at $749.44, down 0.2%, and the company is scheduled to pay a $0.09 dividend on the same day.